住院COVID-19患者静脉血栓栓塞症的管理
本文综述了住院及重症COVID-19患者静脉血栓栓塞症(VTE)高发的机制与特点,指出标准血栓预防下VTE发生率仍异常升高,并汇总了国际血栓与止血学会科学与标准化委员会等指南对诊断、预防和治疗的推荐,强调正在进行的随机试验将评估更强化的血栓预防策略。
要点
- 住院及重症COVID-19患者VTE(尤其肺栓塞)发生率高于历史对照。
- 标准血栓预防下VTE发生率仍异常升高,提示中间剂量或按体重调整肝素可能更有效。
- 国际血栓与止血学会科学与标准化委员会指南涵盖诊断、预防和治疗。
核心结论
- 住院及重症COVID-19患者VTE发生率高,标准血栓预防下仍异常升高,中间剂量或按体重调整肝素可能对高危亚组更有效。
研究设计与样本
- 本文为综述,汇总住院及重症COVID-19患者VTE管理的指南与证据。
主要发现
- 与历史对照相比,住院及重症COVID-19患者VTE(尤其肺栓塞)发生率高。
- 发现与微血栓相关的原位肺栓塞,提示除经典大血管病变外还存在血栓性微血管病过程。
- 标准血栓预防下VTE发生率仍异常升高,提示中间剂量或按体重调整肝素可能比固定剂量更有效。
关键数值与推荐
- 国际血栓与止血学会科学与标准化委员会最新声明对住院及重症COVID-19患者VTE的诊断、预防和治疗提供了全面指导。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The high incidence of thromboembolic disease, and in particular venous thromboembolism (VTE), has emerged as an important consideration in hospitalized and critically ill patients with coronavirus disease 2019 (COVID-19). The coagulopathy of COVID-19 is postulated to result from interactions of the inflammatory and immune systems with the coagulation system, manifesting as a cytokine storm associated with hyperinflammation and coagulation and platelet activation. Unique characteristics of VTE in hospitalized and critically ill patients with COVID-19 include the high incidence of VTE (and especially pulmonary embolism) when compared with historical controls; the finding of in situ pulmonary embolism associated with microthrombi, which suggests a thrombotic microangiopathic process in addition to classic macrovessel disease; and, most important from a clinical perspective, the unusually high rate of VTE that has been reported despite standard thromboprophylaxis. This raises the possibility that intermediate or weight-based heparin dosing may be more effective than fixed dosing for thromboprophylaxis in high-risk subsets of patients hospitalized with COVID-19. There have been several guidance statements focusing on the management of VTE in hospitalized and critically ill patients with COVID-19, including the most recent statement by the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis, which includes comprehensive guidance on the diagnosis, prevention, and treatment of VTE in this patient population. Ongoing randomized trials that address key clinical questions, especially more intense thromboprophylactic strategies and novel antithrombotic approaches, have the potential to reduce the morbidity and mortality from VTE in hospitalized and critically ill patients with COVID-19.
引用
- Spyropoulos AC. The management of venous thromboembolism in hospitalized patients with COVID-19. Blood Adv. 2020. PMID: 32841342. doi:10.1182/bloodadvances.2020002496
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。